Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SORD antisense RNA 1 (SORD-AS1) is a long noncoding RNA (lncRNA) gene. It is an antisense transcript oriented opposite to the protein-coding SORD (sorbitol dehydrogenase) gene. SORD-AS1 does not encode a protein; instead, like other antisense RNAs, it may regulate the expression of its sense gene or other targets at the RNA level, though direct functional or disease associations have not been described for SORD-AS1 specifically[5]. Generally, antisense RNAs can control gene expression through various mechanisms including transcriptional interference, alteration of chromatin structure, or influencing mRNA stability and translation[1][3][7]. There are currently no drugs, disease markers, or safety concerns linked to SORD-AS1, and it is not classified as a therapeutic target.
None described for SORD-AS1, as no drugs act on this RNA. General mechanisms for antisense RNAs include modulation of mRNA stability, translation, and chromatin state, but these are not reported specifically for SORD-AS1
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SORD antisense RNA 1 (SORD-AS1).